{"title":"益生菌对轻度认知障碍和阿尔茨海默病患者选择认知领域的影响:一项系统综述和荟萃分析。","authors":"Shashank Tripathi, Meenakshi Kaushik, Rekha Dwivedi, Prabhakar Tiwari, Manjari Tripathi, Rima Dada","doi":"10.1177/25424823241289039","DOIUrl":null,"url":null,"abstract":"<p><strong>Background: </strong>Mild cognitive impairment (MCI) and Alzheimer's disease (AD) are progressive neurodegenerative disorders, and probiotics may offer therapeutic benefits by modulating gut microbiota and reducing inflammation.</p><p><strong>Objective: </strong>This study systematically evaluated the impact of probiotics on cognitive function in MCI and AD through a meta-analysis of randomized controlled trials (RCTs).</p><p><strong>Methods: </strong>A systematic review and meta-analysis were performed following PRISMA 2020 guidelines. PubMed, Embase, EBSCO, and Cochrane databases were searched for RCTs (January 2000-January 2024) on probiotic interventions lasting 8-24 weeks. Cognitive outcomes included Mini-Mental State Examination (MMSE), Montreal Cognitive Assessment (MoCA), language, naming, visual-spatial, memory, and attention. Data were analyzed using R with a random-effects model to calculate pooled standardized mean differences (SMDs) with 95% confidence intervals (CIs). Risk of bias was rigorously assessed.</p><p><strong>Results: </strong>Out of 2000 articles, 500 full texts were screened, and 10 studies were included. The meta-analysis showed varied effect sizes: MMSE (SMD: 0.28, 95%CI -0.35-0.91, p = 0.38), MoCA (SMD: 0.51, 95%CI -0.49-1.52, p = 0.33), language (SMD: -0.12, 95% CI -0.54-0.29, p = 0.56), naming (SMD: 0.02, 95%CI -0.69-0.74, p = 0.95), visual-spatial (SMD: 0.38, 95%CI -0.13-0.88, p = 0.14), memory (SMD: 0.20, 95%CI -0.15-0.55, p = 0.26), and attention (SMD: -0.07, 95%CI -0.44-0.30, p = 0.71). Positive SMDs suggest cognitive improvement, while non-significant negative SMDs indicate trends toward decline, inclined by probiotic strains, duration, and participant characteristics.</p><p><strong>Conclusions: </strong>Probiotics did not significantly improve cognitive function in MCI and AD patients, with variability in effects across cognitive domains, suggesting the need for tailored interventions and future studies.</p>","PeriodicalId":73594,"journal":{"name":"Journal of Alzheimer's disease reports","volume":"8 1","pages":"1422-1433"},"PeriodicalIF":2.8000,"publicationDate":"2024-10-18","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11863739/pdf/","citationCount":"0","resultStr":"{\"title\":\"The effect of probiotics on select cognitive domains in mild cognitive impairment and Alzheimer's disease: A systematic review and meta-analysis.\",\"authors\":\"Shashank Tripathi, Meenakshi Kaushik, Rekha Dwivedi, Prabhakar Tiwari, Manjari Tripathi, Rima Dada\",\"doi\":\"10.1177/25424823241289039\",\"DOIUrl\":null,\"url\":null,\"abstract\":\"<p><strong>Background: </strong>Mild cognitive impairment (MCI) and Alzheimer's disease (AD) are progressive neurodegenerative disorders, and probiotics may offer therapeutic benefits by modulating gut microbiota and reducing inflammation.</p><p><strong>Objective: </strong>This study systematically evaluated the impact of probiotics on cognitive function in MCI and AD through a meta-analysis of randomized controlled trials (RCTs).</p><p><strong>Methods: </strong>A systematic review and meta-analysis were performed following PRISMA 2020 guidelines. PubMed, Embase, EBSCO, and Cochrane databases were searched for RCTs (January 2000-January 2024) on probiotic interventions lasting 8-24 weeks. Cognitive outcomes included Mini-Mental State Examination (MMSE), Montreal Cognitive Assessment (MoCA), language, naming, visual-spatial, memory, and attention. Data were analyzed using R with a random-effects model to calculate pooled standardized mean differences (SMDs) with 95% confidence intervals (CIs). Risk of bias was rigorously assessed.</p><p><strong>Results: </strong>Out of 2000 articles, 500 full texts were screened, and 10 studies were included. The meta-analysis showed varied effect sizes: MMSE (SMD: 0.28, 95%CI -0.35-0.91, p = 0.38), MoCA (SMD: 0.51, 95%CI -0.49-1.52, p = 0.33), language (SMD: -0.12, 95% CI -0.54-0.29, p = 0.56), naming (SMD: 0.02, 95%CI -0.69-0.74, p = 0.95), visual-spatial (SMD: 0.38, 95%CI -0.13-0.88, p = 0.14), memory (SMD: 0.20, 95%CI -0.15-0.55, p = 0.26), and attention (SMD: -0.07, 95%CI -0.44-0.30, p = 0.71). Positive SMDs suggest cognitive improvement, while non-significant negative SMDs indicate trends toward decline, inclined by probiotic strains, duration, and participant characteristics.</p><p><strong>Conclusions: </strong>Probiotics did not significantly improve cognitive function in MCI and AD patients, with variability in effects across cognitive domains, suggesting the need for tailored interventions and future studies.</p>\",\"PeriodicalId\":73594,\"journal\":{\"name\":\"Journal of Alzheimer's disease reports\",\"volume\":\"8 1\",\"pages\":\"1422-1433\"},\"PeriodicalIF\":2.8000,\"publicationDate\":\"2024-10-18\",\"publicationTypes\":\"Journal Article\",\"fieldsOfStudy\":null,\"isOpenAccess\":false,\"openAccessPdf\":\"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11863739/pdf/\",\"citationCount\":\"0\",\"resultStr\":null,\"platform\":\"Semanticscholar\",\"paperid\":null,\"PeriodicalName\":\"Journal of Alzheimer's disease reports\",\"FirstCategoryId\":\"1085\",\"ListUrlMain\":\"https://doi.org/10.1177/25424823241289039\",\"RegionNum\":0,\"RegionCategory\":null,\"ArticlePicture\":[],\"TitleCN\":null,\"AbstractTextCN\":null,\"PMCID\":null,\"EPubDate\":\"2024/1/1 0:00:00\",\"PubModel\":\"eCollection\",\"JCR\":\"Q2\",\"JCRName\":\"NEUROSCIENCES\",\"Score\":null,\"Total\":0}","platform":"Semanticscholar","paperid":null,"PeriodicalName":"Journal of Alzheimer's disease reports","FirstCategoryId":"1085","ListUrlMain":"https://doi.org/10.1177/25424823241289039","RegionNum":0,"RegionCategory":null,"ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"2024/1/1 0:00:00","PubModel":"eCollection","JCR":"Q2","JCRName":"NEUROSCIENCES","Score":null,"Total":0}
引用次数: 0
摘要
背景:轻度认知障碍(MCI)和阿尔茨海默病(AD)是进行性神经退行性疾病,益生菌可能通过调节肠道微生物群和减少炎症提供治疗益处。目的:本研究通过随机对照试验(RCTs)的荟萃分析,系统评估益生菌对MCI和AD患者认知功能的影响。方法:按照PRISMA 2020指南进行系统评价和荟萃分析。检索PubMed、Embase、EBSCO和Cochrane数据库,检索2000年1月至2024年1月期间有关益生菌干预8-24周的随机对照试验。认知结果包括简易精神状态检查(MMSE)、蒙特利尔认知评估(MoCA)、语言、命名、视觉空间、记忆和注意力。采用随机效应模型计算95%置信区间(ci)的合并标准化平均差(SMDs),采用R法对数据进行分析。对偏倚风险进行了严格评估。结果:在2000篇文章中,筛选了500篇全文,纳入了10项研究。meta分析显示不同的效应大小:MMSE (SMD: 0.28, 95%CI -0.35-0.91, p = 0.38)、MoCA (SMD: 0.51, 95%CI -0.49-1.52, p = 0.33)、语言(SMD: -0.12, 95%CI -0.54-0.29, p = 0.56)、命名(SMD: 0.02, 95%CI -0.69-0.74, p = 0.95)、视觉空间(SMD: 0.38, 95%CI -0.13-0.88, p = 0.14)、记忆(SMD: 0.20, 95%CI -0.15-0.55, p = 0.26)、注意力(SMD: -0.07, 95%CI -0.44-0.30, p = 0.71)。积极的smd表明认知改善,而不显著的消极smd表明有下降的趋势,这与益生菌菌株、持续时间和参与者特征有关。结论:益生菌并没有显著改善MCI和AD患者的认知功能,在不同的认知领域有不同的效果,这表明需要量身定制的干预措施和未来的研究。
The effect of probiotics on select cognitive domains in mild cognitive impairment and Alzheimer's disease: A systematic review and meta-analysis.
Background: Mild cognitive impairment (MCI) and Alzheimer's disease (AD) are progressive neurodegenerative disorders, and probiotics may offer therapeutic benefits by modulating gut microbiota and reducing inflammation.
Objective: This study systematically evaluated the impact of probiotics on cognitive function in MCI and AD through a meta-analysis of randomized controlled trials (RCTs).
Methods: A systematic review and meta-analysis were performed following PRISMA 2020 guidelines. PubMed, Embase, EBSCO, and Cochrane databases were searched for RCTs (January 2000-January 2024) on probiotic interventions lasting 8-24 weeks. Cognitive outcomes included Mini-Mental State Examination (MMSE), Montreal Cognitive Assessment (MoCA), language, naming, visual-spatial, memory, and attention. Data were analyzed using R with a random-effects model to calculate pooled standardized mean differences (SMDs) with 95% confidence intervals (CIs). Risk of bias was rigorously assessed.
Results: Out of 2000 articles, 500 full texts were screened, and 10 studies were included. The meta-analysis showed varied effect sizes: MMSE (SMD: 0.28, 95%CI -0.35-0.91, p = 0.38), MoCA (SMD: 0.51, 95%CI -0.49-1.52, p = 0.33), language (SMD: -0.12, 95% CI -0.54-0.29, p = 0.56), naming (SMD: 0.02, 95%CI -0.69-0.74, p = 0.95), visual-spatial (SMD: 0.38, 95%CI -0.13-0.88, p = 0.14), memory (SMD: 0.20, 95%CI -0.15-0.55, p = 0.26), and attention (SMD: -0.07, 95%CI -0.44-0.30, p = 0.71). Positive SMDs suggest cognitive improvement, while non-significant negative SMDs indicate trends toward decline, inclined by probiotic strains, duration, and participant characteristics.
Conclusions: Probiotics did not significantly improve cognitive function in MCI and AD patients, with variability in effects across cognitive domains, suggesting the need for tailored interventions and future studies.